Stock 1177 SINO BIOPHARMACEUTICAL LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Sino Biopharmaceutical Limited

Equities

1177

KYG8167W1380

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:11 2024-05-08 am EDT 		5-day change 1st Jan Change
2.91 HKD +1.04% Intraday chart for Sino Biopharmaceutical Limited +1.04% -16.14%
Apr. 30 Wall Street, Earnings, Federal Reserve Roil Asian Stock Markets MT
Apr. 30 Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Unecritinib Fumarate Capsules CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Wall Street, Earnings, Federal Reserve Roil Asian Stock Markets
Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Unecritinib Fumarate Capsules
Sino Biopharm Completes Phase I Study of Hepatitis B Drug
Lull in Geopolitical Tensions Lifts Asian Stock Markets
Hong Kong shares jump on policy support; China slips
Borse Cina : chiudono miste, in rialzo Hong Kong con decisione su tassi
Hong Kong shares jump 1.5% on policy support; China slips
Sino Biopharmaceutical Limited Announces Category 1 Innovative Drug Rovadicitinib Obtained Positive Results in Key Clinical Research for Registration
Sino Biopharmaceutical Trustee Repurchases Shares
Sino Biopharmaceutical to Develop Boehringer Ingelheim's Cancer Treatments in China
Sino Biopharmaceutical Limited Enters into Strategic Partnership with Boehringer Ingelheim on Innovative Oncology Portfolio in China
Sino Biopharmaceutical's Attributable Profit Drops 8.3% in 2023
Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024
Sino Biopharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2023
Sino Biopharmaceutical's Diagnostic Agent Injection Gets Marketing Nod in China
Sino Biopharmaceutical Limited Announces Approval for Marketing of Iopromide Injection
Sino Biopharmaceutical's Developing Two Drugs for MASH
Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225"
Sino Biopharmaceutical to Present Cancer Drug Phase II Trial Findings at 2024 AACR
Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1177 Stock
  4. News Sino Biopharmaceutical Limited
  5. Other languages
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW